Evelo Forges Ahead In Psoriasis As Atopic Dermatitis Pathway Narrows
Company Reveals Layoffs To Stay On Course
Executive Summary
The company said the first three cohorts of its Phase II atopic dermatitis study failed, while another trial with a faster-release formulation of EDP1815 continues, along with a Phase III study in psoriasis.
You may also be interested in...
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Evelo’s Phase II Data Suggest Strong Position In Mild-To-Moderate Psoriasis
Analysts say biotech’s EDP1815 may offer similar efficacy to Amgen’s Otezla, with better safety. Evelo says data offer new proof for its small intestinal axis approach to inflammatory disease.
FDA Lifts Hold On Blueprint’s CDK2 Inhibitor Trial, Potentially Calming Nerves
The FDA placed a partial hold in February amid ocular adverse event concerns, but soon lifted it. Other CDK2 inhibitors have had ocular toxicity issues as well.